A Prospective, Open, Single-arm, Phase Ⅱ Clinical Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer
Latest Information Update: 25 Jan 2024
At a glance
- Drugs Catequentinib (Primary) ; Tislelizumab (Primary) ; Anthracyclines; Doxorubicin; Epirubicin; Paclitaxel
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms NeoATCT
- 18 Jan 2024 Planned End Date changed from 31 Jul 2023 to 30 Sep 2025.
- 18 Jan 2024 Planned primary completion date changed from 31 Jul 2022 to 31 Mar 2025.
- 07 Jun 2022 Trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology